ESMO 2026 Trials Test Next Steps After Targeted Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer
Start here
Three phase II trials presented at ESMO 2026 examined strategies for BRAF V600E-mutant metastatic colorectal cancer after targeted therapy. ECLYPse met its primary endpoint, TRIDENTE showed clinical activity, and BRICKET recorded no objective responses. Together the results map a diverging landscape of options for a patient population with limited post-targeted-therapy choices, though only one of the three studies hit its primary goal. How the findings will shape sequencing of treatment in this mutation-defined colorectal cancer subset is still unresolved.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.com2026 ESMO: ECLYPse, TRIDENTE and BRICKET Test Post-Targeted-Therapy Strategies in BRAF V600E-Mutant mCRC, ctDNA-Guided Retreatment Shows No Objective Responses
At ESMO 2026, three phase II studies of post-targeted-therapy strategies in BRAF V600E-mutant metastatic colorectal cancer (mCRC) were presented: ECLYPse met its primary endpoint, TRIDENTE showed clinical activity, and BRICKET observed no objective responses.
Heat trend for this story
Heat now 2·Peak in the comparable set 10 (Oct 25 20:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.